Mammalian Vav signal transducer proteins couple receptor tyrosine kinase signals to the activation of the Rho/Rac GTPases, leading to cell differentiation and/or proliferation. The unique and complex structure of mammalian Vav proteins is preserved in the Drosophila melanogaster homologue, DroVav. We demonstrate that DroVav functions as a guanine-nucleotide exchange factor (GEF) for DRac. Drosophila cells overexpressing wildtype (wt) DroVav exhibited a normal morphology. However, overexpression of a truncated DroVav mutant (that functions as an oncogene when expressed in NIH3T3 cells) results in striking changes in the actin cytoskeleton, resembling those usually visible following Rac activation. Dominant-negative DRac abrogated these morphological changes, suggesting that the effect of the truncated DroVav mutant is mediated by activation of DRac. In Drosophila cells, we find that stimulation of the Drosophila EGF receptor (DER) increases tyrosine phosphorylation of DroVav, which in turn associates with tyrosine-phosphorylated DER. In addition, the following results imply that DroVav participates in downstream DER signalling, such as ERK phosphorylation: (a) overexpression of DroVav induces ERK phosphorylation; and (b) 'knockout' of DroVav by RNA interference blocks ERK phosphorylation induced by DER stimulation. Unlike mammalian Vav proteins, DroVav was not found to induce Jnk phosphorylation under the experimental circumstances tested in fly cells. These results establish the role of DroVav as a signal transducer that participates in receptor tyrosine kinase pathways and functions as a GEF for the small RhoGTPase, DRac.
Introduction
The receptor tyrosine kinases (RTKs) play an important role in the control of most fundamental cellular processes including the cell cycle, cell migration, cell metabolism and survival, as well as cell proliferation and differentiation (Schlessinger, 2000) . RTK stimulation leads to the deployment of signalling proteins that relay the appropriate specific signals, resulting in the desired cell fate. Many of the signal transducing proteins, including RTKs, are conserved throughout evolution. In the past few years, genetic and biochemical studies in Drosophila have revealed the identity and function of many signalling cascade molecules that are also shared by mammals (Wassarman et al., 1995; Perrimon and Perkins, 1997; Rebay 2002) . However, there are still many signalling proteins whose roles are still unknown. We have recently isolated and partially characterized one such signal transducer protein, the Drosophila melanogaster homologue of mammalian Vav proteins, DroVav (Dekel et al., 2000) .
Vav proteins represent a novel family of signal transducers that couple tyrosine kinase signals with the activation of the Rho/Rac GTPases and are likely to play an integral role in the regulation of cell differentiation in many tissues. The first member of the mammalian Vav family of cytoplasmic signal transducer proteins to be identified, Vav1, was isolated as an oncogene (Katzav et al., 1989) . Removal of its amino terminus activates Vav1 as a transforming protein (Coppola et al., 1991; Katzav et al., 1991) . Likewise, the corresponding molecular lesions in Vav2 and Vav3, two other members of the mammalian Vav family, render these proteins transforming (Schuebel et al., 1996; Movilla and Bustelo, 1999; Zeng et al., 2000) . Unlike Vav1, which is exclusively expressed in hematopoietic cells, Vav2 and Vav3 are expressed in both hematopoietic cells and in many cells of nonhematopoietic origin (Katzav et al., 1989 (Katzav et al., , 1991 Coppola et al., 1991; Schuebel et al., 1996; Movilla and Bustelo, 1999; Zeng et al., 2000) . Numerous biochemical and overexpression experiments revealed that tyrosine phosphorylation of Vav1 in response to activation by one of several cytokines, growth factors or antigen receptors regulates its activity as a GEF for the Rho/Rac family of GTPases, RhoA, Rac1 and RhoG (Bustelo et al., 1992; Margolis et al., 1992; Crespo et al., 1996 Crespo et al., , 1997 Bustelo, 2000; Turner and Billadeau, 2002) . Activation of these GTPases leads to cytoskeletal reorganization and activation of stress-activated protein kinases (SAPK/ JNKs) in T cells (Crespo et al., 1996 (Crespo et al., , 1997 Bustelo, 2000; Turner and Billadeau, 2002) . Vav2 and Vav3 function in a similar but not identical fashion (Schuebel et al., 1996; Movilla and Bustelo, 1999; Bustelo, 2000; Zeng et al., 2000; Turner and Billadeau, 2002) . While both Vav2 and Vav3 also act as GEFs, there are conflicting reports regarding which GTPases are activated by them, and whether these GTPases are distinct from those activated by Vav1 (Schuebel et al., 1996; Movilla and Bustelo, 1999; Bustelo, 2000; Zeng et al., 2000; Turner and Billadeau, 2002) . Knockout experiments revealed that in T cells, Vav1 integrates signals from lymphocyte antigen receptors and costimulatory receptors to control differentiation, proliferation and the response to activation (Fischer et al., 1998; Holsinger et al., 1998) . Thus, mice deficient in Vav1 exhibit defects in numerous responses to T-cell stimulation, including capping of the T-cell receptor (TCR) postactivation, recruitment of the actin cytoskeleton to the CD3z chain of the TCR, interleukin-2 (IL-2) production and proliferation, cell cycle progression, activity of NF-AT, phosphorylation of SLP-76 and increase in Ca 2 þ influx (Fischer et al., 1998; Holsinger et al., 1998) . Mice deficient in Vav2 display no obvious defects in T-cell development yet exhibited some defects in B-cell function (Doody et al., 2001; Tedford et al., 2001) . Mice lacking both Vav1 and Vav2 displayed major defects in B-cell function that are as dramatic as the defects in T-cell development and activation observed in Vav1 À/À mice (Doody et al., 2001; Tedford et al., 2001 ). Since there are no reports regarding Vav3 À/À mice at the present time, our picture of the intricate signalling network induced by the Vav proteins is incomplete. However, it is obvious that the redundancy and complexity of the mammalian Vav proteins even in hematopoietic cells together with the possibility that they differ both in their protein-protein interactions and in their activation of various GTPases, makes it difficult to clearly interpret the results of knockout and other experiments in mammals.
In Drosophila, only one Vav homologue (DroVav) is present (Dekel et al., 2000) . The highly conserved and unique structure of DroVav suggests that the vav genes probably evolved from one ancestral gene and that they are important regulatory molecules in flies as well as in mammals. DroVav encodes a protein whose similarity with hVav1 is 47% and with hVav2 and hVav3 is 45% (Dekel et al., 2000) . Like mammalian Vav proteins, DroVav encodes a 'calponin-homology' (CH) region, a dbl homology (DH) domain, a pleckstrin homology (PH) domain and both an Src Homology 2 (SH2) and an Src Homology 3 (SH3) domains (Dekel et al., 2000) . However, unlike mammalian Vav proteins, DroVav lacks an amino-SH3 region (Dekel et al., 2000) . DroVav is the only known Drosophila Rho GEF that encodes in addition to a DH region, both SH2 and SH3 domains, attesting that it may be a uniquely versatile signal transducer. The fact that only one homologue of Vav is present in flies, combined with the unique and highly conserved structure of the protein, promises that any study of DroVav in flies should be highly beneficial and instructive.
A hallmark of Vav signal transducer proteins is that their tyrosine residues become phosphorylated on tyrosine residues in response to EGF stimulation (Bustelo et al., 1992; Margolis et al., 1992; Katzav 1993) . Furthermore, Vav proteins are known to bind to the stimulated EGFR through their SH2 region (Bustelo et al., 1992; Margolis et al., 1992; Katzav 1993) . In mammalian cells, DroVav is tyrosine phosphorylated in response to EGFR induction; in vitro, the DroVav SH2 region is associated with tyrosine-phosphorylated EGFR (Dekel et al., 2000) . These results combined with the encoded domain structure of DroVav strongly suggest that DroVav may function as a signal transducer protein in the Drosophila EGF receptor (DER) signalling cascades. Here, we investigate the role of DroVav in downstream signalling from the DER, its interaction with the Drosophila Rac pathway, and its ability to effect cytoskeletal changes in Drosophila cells.
Results

DroVav as a GEF for DRac
One of the major functions attributed to mammalian Vav proteins is their activity as GEFs for Rho family proteins (Bustelo, 2000; Turner and Billadeau, 2002) . Vav1 is a preferential exchange factor for Rac1 both in vitro (Crespo et al., 1996 (Crespo et al., , 1997 and in vivo (Turner and Billadeau, 2002) . Therefore, it was of interest to determine whether DroVav also functions as a GEF for DRac (Figure 1 ). To explore this possibility, we used an assay that is commonly utilized to analyse the exchange activity towards Rac by several GEFs, including Vav (Kuhne et al., 2000; Del Pozo et al., 2003; Johmura et al., 2003) . This assay is based on the specific binding between p21-activated kinase (PAK) and the activated GTP-bound form of Rac1 (Manser et al., 1998) Figure 1 . Accordingly, we show here for the first time that DroVav functions as a GEF for DRac in Drosophila.
DroVav and cytoskeleton organization
In mammalian cells, Vav proteins were shown to localize in the cytoplasm although recruitment of Vav1 to the plasma membrane appears important for its function as a GEF (Rivera et al., 2001 ). Recent studies demonstrate that Vav1 can also translocate to the nucleus under certain stimulatory conditions (Houlard et al., 2002) . As shown in Figure 2 , DroVav is present in the cytoplasm of S2 cells (panel b). Biochemical cell fractionation also confirmed the localization of DroVav in the cytoplasm (data not shown). The morphology of the cells is round and the F-Actin seems to be disorganized, as visualized by confocal microscopy ( Figure 2, panel b) . To exclude the possibility that DroVav is also present in the nucleus, we also stained the cells with propidium iodide that binds to DNA, thus highlighting the position of the nucleus (Figure 2 ; panels c and d). Again, our results clearly demonstrate that the location of DroVav is in the cytoplasm and not in the nucleus.
Mammalian Vav1 was shown to be involved in triggering cytoskeletal changes contributing to modifications in cell shape and motility via its activity as a GEF for Rac1 (Fischer et al., 1998; Holsinger et al., 1998) . Opposing observations were made with regard to the alterations in cell morphology of cells overexpressing wild-type (wt) hVav1 and its amino-terminus-truncated mutant (Ma et al., 1998; Kranewitter and Gimona 1999; Michel et al., 2000) . It was, therefore, of interest to examine whether overexpression of wtDroVav or an amino-terminus-truncated DroVav mutant in Drosophila S2 cells could result in morphological changes indicative of Rac activation ( We then examined whether overexpression of a DroVav mutant causes changes in S2 cell morphology ( Figure 3 ; panel c). For that purpose, we created a deletion mutant of DroVav that lacks 214 amino-acid residues from its amino terminus (oncVav). A similar deletion mutant in mammalian Vav proteins was shown to function as an oncogene (Katzav et al., 1989 (Katzav et al., , 1991 Coppola et al., 1991) . Likewise, the generated Drosophila oncVav generated transformed foci when tested by the NIH3T3 focus forming assay, whereas wtDroVav was nontransforming (data not shown). S2 cells overexpressing oncVav exhibit cellular processes identifiable as typical lamellipodia and microspikes (Figure 3 ; panel Figure 3 ; panel e) yielded a morphology similar to, but more pronounced than that obtained with each of these proteins alone (Figure 3 ; panels c and g). This result supports the possibility that the activation of DRac by oncVav is responsible for the changes in the cytoskeletal reorganization. Taken together, our immunofluorescence microscopy analysis indicates that a mutant DroVav is able to (N17DRac); (e) Myc epitope-tagged oncVav with a constitutive active mutant DRac (V12DRac); (f) Myc epitope-tagged N17DRac and (g) Myc epitopetagged V12DRac. Cells were fixed and immunofluorescence staining was performed using the following reagents: anti-Myc mAbs (detection of transfected wtDroVav) followed by Alexa488-coupled anti-mouse IgG 2a (green); anti-Rac mAbs followed by Alexa633-coupled goat anti-mouse IgG 2b secondary Abs (blue) and F-actin was detected using Alexa546-coupled phalloidin (red). Background levels of endogenous Rac expression was reduced to zero and only cells that overexpress both transfected DRac and DroVav were analysed. Confocal analysis was carried out as described in Figure 2 . The experiment depicted here represents one representative experiment of three performed Vav as a signal transducer protein in Drosophila I Hornstein et al generate morphological alterations in S2 cells reminiscent of those seen following activation of Rac1 and Cdc42 proteins.
DroVav is involved in DER signalling
Activation of DER with Spitz, a DER ligand, stimulates the DER signalling cascade (Schweitzer et al., 1995) . Therefore, addition of a secreted form of Spitz to S2 Drosophila cells overexpressing DER (D2F) gives rise to rapid tyrosine autophosphorylation of DER (Schweitzer et al., 1995) . This in turn leads to the onset of signalling cascades that play a cardinal role in numerous events including cell fate determination during oogenesis, embryogenesis, and the proliferation and differentiation of imaginal discs (Schweitzer and Shilo, 1997) . To examine whether DroVav plays a role as a signalling protein in the DER pathway in the fly, we induced D2F cells with secreted Spitz and followed the pattern of tyrosine phosphorylation of DroVav (Figure 4a ). We observed tyrosine phosphorylation of DroVav only when D2F cells had been stimulated with Spitz ( Figure 4a; upper and lower panels; lanes 2 and 3 vs lane 1). Thus, we conclude that DroVav (92 kDa) is tyrosine phosphorylated following the induction of signalling processes by Spitz and it associates with the tyrosinephosphorylated DER. These results strongly suggest that DroVav is a signal transducer protein that participates in DER signalling.
One of the changes elicited in stimulated cells is manifested by cytoskeleton organization (Ridley and Hall, 1992; Bar-Sagi and Hall, 2000) . We decided to test whether such modifications occur in Spitz-stimulated D2F cells (Figure 4b ). The unstimulated round D2F cells (Figure 4b ; upper panel) exhibited a spiky morphology and its F-actin was only organized after the cells were stimulated with Spitz ( Figure 4b ; lower panel). Thus, it seems that activation of D2F cells by Spitz leads to cytoskeletal changes similar to, though less effective than, those obtained with V12DRac ( Figure 3, panel g ). No major changes in the localization of endogenous DroVav were observed (Figure 4b ).
DroVav influences DER downstream signalling pathways
Following autophosphorylation, DER initiates a signalling pathway that includes the Ras/extracellular signalregulated kinase (ERK) pathway and results in the activation of members of the mitogen-activated protein (MAP) kinase family (Golembo et al., 1996) . These MAP kinases translocate to the nucleus and activate or repress transcription factors (Golembo et al., 1996 (Golembo et al., , 1999 . Since DroVav is tyrosine phosphorylated in response to DER activation (Figure 4) , it is conceivable that it participates in relaying downstream signals. Therefore, we proceeded to clarify whether DroVav can act in the DER/ERK signalling pathway ( Figure 5 ). For this purpose, the level of ERK activation as manifested by its phosphorylation was tested in D2F cells that were transiently transfected with either the vector alone (Figure 5a ; lanes 1 and 2) or a Myc epitopetagged wtDroVav (Figure 5a; lanes 3 and 4) . As expected, in D2F cells transfected with the vector only, an increase in phospho-ERK was noticed only when We next wished to clarify whether DroVav is required for ERK activation. For that purpose, we 'knocked out' DroVav by using the double-stranded RNA (dsRNA)-mediated interference (RNAi) approach. This technique is widely used to facilitate reverse genetic studies in several species, including Drosophila (Clemens et al., 2000; Carthew, 2001) . dsRNA is capable of specifically blocking the production of targeted proteins in cell culture. Transfection of dsRNA directed against the carboxy terminus of DroVav into D2F cells led to the elimination of DroVav protein in these cells as compared to cells transfected with vector only (Figure 5b, upper panel; lanes 3 and 4 vs lanes 1 and  2) , while the expression of ERK was unaffected (Figure 5b, middle panel, lanes 1-4) . Transfected cells were treated with Spitz and phosphorylation of ERK was examined. Elimination of DroVav from D2F cells abrogated the increase in phospho-ERK normally observed in D2F cells expressing DroVav (Figure 5b , lane 4 vs lane 2; lower panel). The fact that no increase in phosphorylation of ERK above the basal level is observed in the absence of DroVav indicates that it plays a cardinal role in the ERK signalling pathway.
DroVav and the DJNK pathway
Another mitogen-activated protein kinase (MAPK) signalling pathway that is influenced by Vav proteins in mammals is the JNK pathway (Crespo et al., 1996; Fischer et al., 1998; Holsinger et al., 1998; Cao et al., 2002) . The stimulation of JNK by Vav1 is dependent on its function as a GEF towards Rac (Crespo et al., 1996; Hehner et al., 2000) . We therefore analysed whether DroVav is involved in the highly conserved JNK pathway in Drosophila (Figure 6 ). Since DroVav is tyrosine phosphorylated following stimulation of DER by Spitz (Figure 4a ), we first examined the possibility that JNK is activated in response to DER stimulation, perhaps in a DroVav-dependent manner. However, no increase in the phosphorylation of JNK following stimulation of D2F cells with Spitz even in cells overexpressing wtDroVav or oncVav could be observed (data not shown). Hence, JNK is not activated by DER in D2F cells and even DroVav could not lead to its activation. Sorbitol osmotic shock was shown to induce JNK phosphorylation in S2 cells (Chen et al., 2002) . (Figure 6b ; lanes 5 and 6) had no effect on JNK phosphorylation as compared to its level of phosphorylation in S2 cells transfected with vector alone (Figure 6b ; lane 2). To further substantiate these results, we used the RNAi methodology to eliminate DroVav expression (Figure 6b ; lanes 7 and 8). However, even loss of DroVav expression did not affect the activation of JNK by sorbitol (Figure 6b ; lane 8 vs lane 7). Together, these results demonstrate that DroVav does not participate in the activation of JNK by osmotic shock in S2 cells. 
Discussion
We demonstrate here for the first time that DroVav can activate DRac in vivo (Figure 1) . DRac was shown in Drosophila to be involved in various cellular processes including cell shape, cell adhesion, gene transcription, protein trafficking and cell cycle progression, as well as numerous developmental processes (Settleman, 2001) . One of the best known characteristics of Rac is that it is involved in actin cytoskeletal organization (Ridley and Hall, 1992; Bar-Sagi and Hall, 2000) . Indeed, the expression of a constitutively activated form of DRac (V12DRac) in S2 cells causes marked changes in the morphology of the cells, leading to lamellipodia and microspikes (Figure 3) . Our results indicate that overexpression of oncVav, but not wtDroVav, can induce a morphology similar to that obtained with V12DRac (Figures 3) . The fact that N17DRac inhibits the changes in the morphology obtained with oncVav ( Figure 3 ) further substantiates our conclusion that the activation of DRac by DroVav is responsible for the observed cytoskeletal reorganization. Correspondingly, an inactive hVav1 variant defective in its ability to activate Rac inhibited the ability to induce actin cytoskeletal organization (Ma et al., 1998) , thus further supporting the tight association between Vav, Rac and actin organization. Notably, coexpression of oncVav and V12DRac led to more profound changes in cytoskeleton organization compared to those observed in cells overexpressing each protein alone (Figure 3) . This result could be explained by the fact that the sum of activation reached by both the endogenous DRac activated by oncVav as well as the constitutively activated DRac yields a more striking morphology. Consistent with our results with wtDroVav, wt hVav1 did not cause any change in morphology of NIH3T3 cells (Kranewitter and Gimona, 1999) and COS cells (Ma et al., 1998) . Conversely, Michel et al. (2000) observed a remarkable change in actin organization following overexpression of hVav1 in T cells. These conflicting results obtained with mammalian wtVav1 could stem from the use of different experimental systems, including the strong possibility that different levels of endogenous Vav2 and Vav3 exist in these systems. The cytoskeletal changes in S2 cells transfected with oncVav are compatible with a previous study demonstrating that an amino-terminus-truncated hVav1 caused depolarization of fibroblasts and triggered the bundling of actin stress fibers in NIH3T3 cells (Kranewitter and Gimona, 1999) . Taken together, our results support a pathway in which DroVav serves as a GEF for DRac, thereby triggering the reorganization of the actin cytoskeleton.
We demonstrate here that DroVav is tyrosine phosphorylated in response to stimulation of DER and it also associates with the stimulated receptor (Figure 4 ). This result is compatible with the known characteristics of mammalian Vav proteins. For example, when ectopically expressed in nonhematopoietic cells, Vav1 associates with the EGFR through its SH2 region and becomes tyrosine phosphorylated upon induction with EGF (Bustelo et al., 1992; Margolis et al., 1992; Katzav, 1993) . A similar result was reported for the ubiquitously expressed Vav2 (Pandey et al., 2000; Tamas et al., 2001 Tamas et al., , 2003 and Vav3 proteins (Zeng et al., 2000) . Although it is well established that the Vav proteins are tyrosine phosphorylated upon EGFR stimulation, the exact contribution of the various mammalian Vav proteins to the EGFR signalling pathway is not understood. Our studies with DroVav shed some light on these events. Thus, we demonstrate here that overexpression of DroVav in D2F cells leads to increased ERK phosphorylation (Figure 5a ). Moreover, its elimination by the use of dsRNAi blocks phosphorylation of ERK even following stimulation of DER (Figure 5b ). There are opposing results regarding the link between Vav and ERK activation in mammals. Overexpression of Vav1 in Jurkat T cells induced 3-4-fold activation of ERK activation (Villalba et al., 2000) . coimmunoprecipitates with ERK in a human myeloma cell line stimulated with interleukin-6 (IL-6; Lee et al., 1997) . Finally, T cells deficient in Vav1 exhibit defects in ERK phosphorylation (Costello et al., 1999) . Conversely, the activation of Ras and ERK following stimulation of the TCR in Vav1 null Jurkat T cells appeared normal (Cao et al., 2002) . Without the complication of multiple homologues, our studies strongly suggest a role for DroVav in the ERK pathway in S2 cells. Despite the existence of several studies that point to a link between hVav1 and Ras (Bustelo et al., 1994; Katzav et al., 1995; Wu et al., 1995) , it is still unclear how Vav proteins can affect ERK. DroVav may affect the Ras/ERK pathway through its function as a GEF towards DRac. Cross talk between the Rac and Ras pathways has been shown to exist in mammals (Bar-Sagi and Hall, 2000) . Rho family small GTPases were found to play an important role in mediating the activation of Raf by Ras (Li et al., 2001) . Thus, a dominant-negative mutant of Rac can block Raf activation by Ras. Additionally, the effect of Rac can be substituted by the PAK kinase, which is a direct downstream target of Rac (Li et al., 2001) . Moreover, PAK directly associates with Raf-1 under both physiological and overexpressed conditions (Zang et al., 2002) . The extent of interaction between PAK and Raf-1 is correlated with the ability of PAK to phosphorylate Raf and induce mitogenactivated protein kinase activation (Zang et al., 2002) . These studies strongly suggest that cross talk between Rac and Ras exist and it is mediated through activation of downstream effectors of Rac, such as PAK (Li et al., 2001; Zang et al., 2002) . Furthermore, it was demonstrated that MEK kinases are regulated by EGF and selectively interact with Rac/Cdc42 (Fanger et al., 1997) . Sotillos and Campuzano (2000) recently identified a novel Drosophila gene, DRacGAP, which behaves as a negative regulator of the GTPases, DRac1 and DCdc42. Reduced function of DRacGAP or increased expression of DRac1 in the wing imaginal disk caused effects on vein and sensory organ development and cell proliferation as a result of enhanced activity of the EGFR/Ras signalling pathway (Sotillos and Campuzano, 2000) . Thus, DRac and DRas are involved in cross-talk mechanisms that modulate Drosophila development (Sotillos and Campuzano, 2000) .
DroVav might also activate ERK in a GEF-independent manner. For instance, DroVav might stimulate the Ras/ERK pathway via PLCg activation, just as Vav1 was shown to activate PLCg (Costello et al., 1999; Reynolds et al., 2002) . PLCg contributes to the activation of Ras, probably by stimulating the activity of the diacylglycerol-dependent exchange factor, Ras GRP (Ebinu et al., 1998; Lorenzo et al., 2000) . It is highly conceivable that the activity of hVav1 towards PLCg is mediated in a GEF-independent mode (Jordan et al., 2003) . Whether such a mechanism is also elicited in flies remains to be determined. DroVav contains several protein-binding domains (SH2, SH3) that might participate in various pathways that result in activation of the Ras/ERK pathway. For instance, DroVav may bind to the adapter molecule DShc, that was shown to be associated with the Grb2/Drk proteins leading to DRas activation (Luschnig et al., 2000) . Indeed, mammalian Shc binds mammalian Vav proteins (Ramos-Morales et al., 1994) . Collectively, our results clearly illustrate that DroVav influences both the DRac and ERK pathways. However, it is not clear yet whether it exerts its influence on ERK by an exclusive inducement of the DRac pathway and/or through a GEFindependent activity.
The involvement of mammalian Vav proteins, by functioning as GEFs towards Rac in the JNK signalling cascade, is well established (Hehner et al., 2000; Kaminuma et al., 2001; Moller et al., 2001) . Moreover, Vav proteins mediate this response through their function as GEFs towards Rac (Hehner et al., 2000; Kaminuma et al., 2001; Moller et al., 2001 ). This pathway is highly conserved between mammals and flies. In Drosophila, it can transduce signals of a diversified nature, leading to changes in cell polarity (Hou et al., 1997) and mediating immunity in the adult (Sluss et al., 1996) . It is also required for dorsal closure during embryonic development (Riesgo-Escovar and Hafen, 1997) . Genetic studies focusing on these processes placed the Rho family small GTPases in the JNK signalling cascade (reviewed in Noselli and Agnes, 1999) . However, although we demonstrate that DroVav functions as a GEF towards DRac in Drosophila (Figure 1 ), DroVav does not seem to be involved in the sorbitol-induced JNK activation ( Figure 6 ). In accordance, Chen et al. (2002) did not detect an effect of Rho family small GTPases on sorbitol-induced JNK activation in S2 cells. It is therefore conceivable that in S2 cells, the sorbitol-induced activation of JNK is not mediated through activation of DRac, and therefore does not require DroVav. The possibility that DroVav is involved in JNK activation under other physiological pathways in Drosophila, such as dorsal closure, still exists; however, this question merits further investigation.
In summary, our results show that, in fly cells, DroVav functions in various signalling cascades in which it can play a role as a GEF or participate as an adapter protein. A P-element insertion has recently been reported to inactivate DroVav, leading to lethality of flies (Bourbon et al., 2000) . Further genetic experiments will be required to better understand the physiological function of DroVav in developmental systems.
Materials and methods
Construction of expression plasmids
Full-length Myc tagged DroVav (pRmHa-wtDroVav) was generated by PCR amplification using the following primers: 5 0 -CCGGGGGAATTCAT GGCCAGCAGCAGT-3 0 and 5 0 -CCGGGGGGTACCGGCGCTATTCAG-3 0 . The mammalian expression vector DroVav-Myc/pSecTag was used as a template (Dekel et al., 2000) . The PCR product was digested with EcoRI/Kpnl (underlined above) and subcloned at the EcoRI/Kpnl sites of the copper-inducible pRmHa-3 vector generating an inducible, Myc-tagged construct. The DroVav mutant lacking 214 N-terminal residues (pRmHa-oncVav) was generated by PCR amplification using the following primers: 5 0 -CCGGGGGAATTCATGGAGCAGCGCGACT AT-3 0 and 5 0 -CCGGGGGGTACCGGCGCTAT TCAG-3 0 and the DroVav-Myc/pSecTag plasmid as a template. The product was subcloned at the EcoRI/Kpnl sites of the pRmHa-3 vector. Both PCR products described (wtDroVav and oncVav) were also subcloned in the Drosophila expression vector pPacPL (http://www.fruitfly.berkely.edu/) in two steps: the PCR products were first subcloned into the EcoRI/Kpnl sites of pBlueScript KS (Stratagene). The generated plasmids were digested with SpeI/KpnI and the inserts were subcloned into the SpeI/KpnI sites of the pPacPL vector, to generate pPacPL-DroVav-wt and pPacPL-oncVav. The DRacl mammalian expression vector (DRacl-pSecTag) was derived by PCR (primers: 5 0 -GGCGGGGCTAGCATGCAGGCGAT-CAAGTGC-3 0 and 5 0 -GGCGGGGAATTCGAGCAGGGC GCACTTCG-3 0 , and a Drosophila cDNA library as a template). The product was digested with NheI/EcoRI and subcloned at the NheI/EcoRI sites of the Myc-tagged pSecTag-A vector (Invitrogen). The DRacl Drosophila expression vector (pRmHa-DRacl) was generated by PCR (primers: 5 0 -GGCGGGGGTACCATGCAGGCGATCAAGTGC-3 0 and 5 0 -CCGGGGGGTACCGGCGCTATTCAG-3 0 , and DRaclpSecTag as a template). The product was subcloned at the KpnI site of the Drosophila pRmHa-3 expression vector. The DRacl mutants; DracV12 and DracN17 were generated by digesting the plasmids DracV12-pJG4 and DracN17-pJG4, received from Dr N Harden with EcoRI/XhoI and subcloning the DNA fragments in the EcoRI/XhoI sites of pBlueScript KS. The generated plasmids were digested with SpeI/KpnI and the insert was subcloned into the SpeI/KpnI sites of the pPacPL expression vector. The haRASwt were received from Dr M Therrien, and previously described in Therrien et al. (1999) .
Antibodies and immunofluorescence reagents
Antibodies (Abs) were obtained from the following sources: rabbit polyclonal Anti DroVav Abs were generated against the following amino-acid residues: KSEHERDKWRKAL-TEAMES (524-542). Monoclonal anti-phosphotyrosine (Ptyr) Abs (mAbs), 4G10, anti-Myc mAbs (clone 9E10); Anti ERK Abs; anti-HA mAbs; polyclonal anti-Rac Abs; and antiPhospho-Jnk mAbs were purchased from UBI (Upstate Biotechnology, Lake Placid, NY, USA). Anti-Phospho-ERK mAbs were purchased from Cell Signaling Technologies. Polyclonal anti DER Abs were received from Professor B Shilo. The following reagents were used for the immunostaining experiments: Alexa488-coupled goat anti-rabbit IgG, Alexa546-coupled phalloidin, Alexa488-coupled anti-mouse IgG 2a and Alexa633-coupled goat anti-mouse IgG 2b secondary Abs (Molecular Probes, Eugene, OR, USA).
Cell culture and transfection S2 Schneider cells were grown at 271C in Schneider's medium (Beit-Haemek, Israel), supplemented with 10% fetal calf serum (FCS), 100 U/ml penicillin and 100 mg /ml streptomycin. The S2: Sspi, S2 cells that overexpress and secret Spitz and S2: D2F, S2 cells that overexpress DER, stable cell lines were obtained from Professor B Shilo. Selection was maintained using 1 mg/ml Genticin, G-418 (Sigma) in the Schneider's growth medium. HEK293 cells were grown in DMEM supplemented with 10% FCS. The calcium phosphate precipitate method of transfection was used for all transient transfections.
Cell stimulation
The DER activation assay was performed as previously described (Schweitzer et al., 1995) . To induce the sorbitol osmotic shock, S2 cells were incubated with 0.5 m sorbitol for 10 min, and then washed three times with PBS kept at room temperature.
Rac activation assay
For the GEF assay, lysates of HEK293 cells, transfected as indicated in the Results section were incubated with glutathione S-transferase-PAK 70-106 bound to a glutathione spin column for 15 min at 41C with continuous mixing as reported by Manser et al. (1998) . After incubation, lysates were spun away from the beads, and the beads were washed three times with 500 ml of lysis buffer and then spun away. Rac was eluted from the beads by transferring the bead-containing spin column to a fresh catch tube, resuspending the beads in reducing sample buffer, heating the column and beads to 951C for 5 min and spinning the eluted samples into the catch tube.
Immunoprecipitation and Western blotting
Cells were lysed in 1% Triton X-100 lysis buffer with protease and phosphatase inhibitors. Cell extracts were immunoprecipitated for 1-5 h with the indicated Abs. The resulting immune complexes were harvested with protein A-sepharose beads (Pharmacia, Peapack, NJ, USA) and resolved by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). Proteins were then transferred to nitrocellulose and immunoblotted with Abs described in the Results section. Blots were detected by enhanced chemiluminescence (ECL) (Pierce) followed by autoradiography, as described previously (Dekel et al., 2000) .
RNA interference in S2 cells
A DNA fragment of 550 bp was generated by PCR, using the following primers, containing a 5 0 T7 RNA polymerase binding site: sense primer -5 0 -GAATTAATACGACTCAC-TATAGGGAGAAATTGGTTTGCGGGC-3 0 and antisense -5 0 -GAATTAATACGACTCACTATAGGGAGAAACCTCG TAGTTGTA-3 0 . The PCR product was purified and used as a template using a MEGASCRIPT T7 transcription kit (Ambion, Austin, TX, USA) to produce double stranded (ds) RNA. The dsRNA product was purified by phenol extraction, followed by ethanol precipitation and resuspended in water. The dsRNA was annealed by incubation at 651C for 30 min followed by slow cooling to room temperature. The dsRNA was then analysed on an agarose gel to confirm that the majority of the dsRNA existed as a single band of 550 bp. A volume of 15 mg of dsRNA per well (six-well plate) was used for transfection, using the calcium phosphate precipitation method.
Immunofluorescence microscopy
The procedure we followed was similar to the one previously published (Roumier et al., 2001; Groysman et al., 2003) . Briefly, D2F or S2 cells both nontransfected or transfected were resuspended in medium without serum and placed on poly-l-lysine-coated coverslips 4 h prior to staining. Cells were then fixed for 30 min at room temperature in 4% paraformaldehyde. Intracellular proteins were stained in 0.05% saponin. For detection of nuclei, cells propidium iodide during the staining with the second Abs. Immunofluorescence and confocal microscopy analysis were performed as previously described (Roumier et al., 2001; Groysman et al., 2003) .
